56 results about "Human rotavirus" patented technology

A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.

A purification preparation method of human rotavirus inactivated vaccines by utilizing ion exchange chromatography relates to a preparation method of virus inactivated vaccines. The purification preparation method comprises concentrating virus harvest liquid, performing chromatographic purification on the concentrated virus harvest liquid through a Qsepharose Fast Flow ion exchange column, performing dialysis desalting on a purified product, and filtering, degerming, inactivating and the like to obtain the human rotavirus inactivated vaccines; and further detecting the purification, the totalprotein removal rate and the infectious titer, and then detecting the antigenicity, the immunogenicity and the genome banding pattern stability. The total protein removal rate of the purified virus harvest liquid is 99.69%, and the infectious titer of the virus before purification and the infectious titer of the virus after purification are respectively 4.25 lg CCID 50 / ml and 7.0 lg CCID 50 / ml, the genome banding pattern of purified virus after inactivation does not mutate, and antigenicity and immunogenicity are kept to be good.

A human rotavirus-A seed strain ZTR-68 is submitted to CGMCC (china general microbiological culture collection center) for preservation in September 22th, 2011, and encoded as CGMCC No.5265. The strain is a human rotavirus wide-type single purified strain, which is high in virus replication and fine in genetic stability. The human rotavirus-A seed strain ZTR-68 is applicable to developing and producing virus seeds for human rotavirus vaccines, and applicable to attenuated rotavirus oral vaccines and inactivated human rotavirus injection vaccines. The invention further provides a method for isolation, culture and identification of the human rotavirus-A seed strain ZTR-68.

The invention relates to pichia pastoris for expressing rotavirus expression particles as well as a preparation method and application of the pichia pastoris, and discloses a human rotavirus structural protein expression cassette, comprising the following elements: (a) an initial signal element AOX; (b) a rotavirus structural protein gene; and (c) a termination signal element TT. The invention further discloses a yeast cell transfected by using the expression cassette, a method for preparing the rotavirus viroid particles by using the yeast cell, viroid particles prepared by using the method, and application of the viroid particles for preparing vaccine compositions for preventing or treating rotavirus infection. The invention also discloses a preparation method of the yeast cell.

The invention relates to human rotavirus Delta VP8* subunit recombinant protein and application thereof. The human rotavirus Delta VP8* subunit recombinant protein comprises a T cell epitope P2 in tetanus toxin and a rotavirus Delta VP8* subunit. By the recombinant protein disclosed by the invention, the immune efficacy of a Delta VP8* subunit vaccine can be greatly improved; faster and stronger neutralization antibody titer can be induced; moreover, anti-p[4] genotype specific rotavirus cross neutralization antibody of high titer can be induced; simultaneously, the potential risk of inducing intussusception by taking attenuated rotavirus vaccine orally can be overcome; therefore, the recombinant protein is applicable to preparing a rotavirus vaccine.

The present invention relates to a VP7 gene of human rotavirus and a composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof, and more particularly to a VP7 gene encoding the amino acid sequence set forth in SEQ ID NO:2 and a composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof. The human rotavirus VP7 gene according to the present invention will be useful for diagnosis of novel G11 type human rotavirus infection, and will be used for development of rotavirus vaccine.

The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.

The invention relates to a human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein, wherein the amino acid sequence of the protein is shown in SEQ ID NO.2. Furthermore, the invention provides a coding gene and a preparation method of the protein as well as an application of the protein in preparation of a rotavirus vaccine. Two segments P[8]deltaVP8* and P[6]deltaVP8* are connected in serial to be expressed into the human rotavirus P[8]deltaVP8*-P[6]deltaVP8* recombinant chimeric protein; the protein can simultaneously induce neutralizing antibodies of major P genotypes P [8], P[4] and P[6] of the human rotavirus, overcome the shortcoming of an existing vaccine which can induce the generation of an antibody only capable of resisting one genotype and greatly enhance immune efficiency; and meanwhile, the protein can avoid a potential risk that oral administration of attenuated vaccine rotavirus possibly induces intestinal invagination, and is applicable to preparation of rotavirus vaccine.

Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.

The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.

A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.

The present invention provides a human rotavirus VP8 recombinant protein, the amino acid sequence of the VP8 recombinant protein includes the amino acid sequence of the human rotavirus VP8 protein (hereinafter referred to as VP8 protein) and the amino acid sequence of an exogenous polypeptide, the exogenous polypeptide The isoelectric point of is less than or equal to 5. The invention also provides a human rotavirus vaccine prepared based on the VP8 recombinant protein. Compared with the prior art, the VP8 recombinant protein provided by the application is expressed through the fusion expression of the VP8 protein and the polypeptide fragment containing negatively charged amino acids in the tetanus toxin and / or diphtheria toxin protein, which improves the expression of the rotavirus VP8 protein expressed by Escherichia coli. Water solubility and yield, and the obtained fusion protein has good immunity, and the prepared vaccine has good effect.

The glass gene chip for simultaneous detection of Group A, B and C human rotaviruses includes aldehydo treated glass chip, oligonucleotide probe array on the glass chip, contrast and blank spot coating, which includes 6 specific human rotavirus detecting probes in different groups, 1 positive contrast probe, 4 negative contrast probes and black sample application liquid contrast. The detecting probes and the contrast probes are connected with poly(dT)15 as connecting arm, and the probes have C6 radical with amino group in the 5í» end. The present invention also discloses the preparation process and clinical application of the chip. The chip of the present invention adopts multiple PCR amplification mode, may be used in the gene detection and group identification of several groups of human rotaviruses, and has wide latent application foreground in sanitary detection of food, disease prevention and control, and clinical medicine.

The invention provides a method for producing a dustless aseptic environment-friendly gertrude, which comprises the steps of preparing finished underclothes from cotton cloth, and is characterized by also comprising three steps of washing the garment, performing ultraviolet sterilization and packaging under vacuum. In the method, ozone liquid for sterilizing the dustless aseptic underclothes has the high oxidation capacity, and oxygen atoms can oxidize cell walls of bacteria and even penetrate through the cell walls to perform chemical combination with unsaturated bonds in the cell walls to kill the bacteria, so the bacteria are killed by the high reduction potential of the ozone liquid. Therefore, the method has the advantages of removing and inhibiting rickettsia bacteria, chlamydia pathogenic bacteria, mycoplasma pathogenic bacteria, spirochete pathogenic bacteria and the like effectively, killing various pathogenic virus such as influenza virus, hepatitis C virus, human immunodeficiency virus (HIV), human rotavirus (HRV) and the like and reducing pathophoresis effectively.